As the date for Brexit fast approaches, drugmakers are bracing for impact, and AstraZeneca’s one of them. The U.K.-based pharma has taken up three lines of defense to forestall potential supply disruptions. More: AstraZeneca Brexit prep to cost £40M as
read moreThe National Institute for Health and Care Excellence has released new draft guidelines calling for faster treatment of patients with kidney stones experiencing severe pain. More: NICE calls for quicker treatment of kidney stone patients in pain Source: News
read moreThe number of people taking part in NHS clinical research studies sponsored by the life sciences industry has risen dramatically over the last year, show new figures by the National Institute for Health Research (NIHR). More: Record numbers taking part
read moreJanssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults. More: US approves Janssen’s HIV pill Symtuza Source: News
read moreMPs have voted 305-301 that the UK should negotiate to remain part of the European Medicines Agency following Brexit. More: MPs vote for UK to remain part of EMA Source: News
read moreVertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines
read more© 1994 - 2026 B.M. Pharmaceuticals